Aditxt At-Home Covid-19 Drug Fails to Achieve Statistical Significance in Trial
Aditxt At-Home Covid-19 Drug Fails to Achieve Statistical Significance in Trial
By Adriano Marchese
阿德里亞諾·馬爾切斯(Adriano Marchese)
Aditxt Inc. said Friday that a Phase 3 trial evaluating favipiravir, a Covid-19 drug treatment with Appili Therapeutics Inc., failed to reach statistical significance.
Aditxt公司週五表示，評估阿普利治療公司的新冠肺炎藥物法韋拉韋的3期試驗未能達到統計學意義。
Aditxt shares were down 25% at $1.36 in premarket trade.
Aditxt股價在盤前交易中下跌25%，至1.36美元。
The biotech innovation company said the trial which evaluated Avigan/Reeqonus, also known as favipiravir, as a potential at-home treatment for mild to moderate Covid-19 didn't achieve statistical significance on the primary endpoint of time to sustained clinical recovery.
這家生物技術創新公司表示，這項評估Avigan/Reeqonus(也被稱為法維拉韋)作為輕中度新冠肺炎潛在家庭治療藥物的試驗，在持續臨牀康復的主要終點上沒有達到統計學意義。
Appili is a consortium partner of AiPharma Global Holdings LLC.
阿普利是Aipharma Global Holdings LLC的財團合作伙伴。
"We are reviewing and evaluating the announced results and data, and will be discussing them with AiPharma Global to determine the best course of action," Appili co-founder and Chief Executive Amro Albanna said.
Appili聯合創始人兼首席執行官阿姆羅·阿爾班納(Amro Albanna)表示：“我們正在審查和評估已公佈的結果和數據，並將與Aipharma Global進行討論，以確定最佳行動方案。”
Write to Adriano Marchese at adriano.marchese@wsj.com
寫信給Adriano Marchese：adriano.marchese@wsj.com
譯文內容由第三人軟體翻譯。